Navigation Links
Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
Date:9/7/2012

nding.  We may determine such a dose based on an efficacy signal or an acceptable safety profile in the Phase 1b trial and/or upon calculating it from ongoing PET imaging trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor radiation exposure at a given dose level).  Preclinical experiments in vitro (in cell culture) and in more than a dozen in vivo (in animals) models have demonstrated selective killing of cancer cells along with a benign safety profile.  In view of HOT's selective uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in animal models and its non-specific mechanism of cancer-killing (radiation), we are first developing HOT as a monotherapy for solid tumors with significant unmet medical need.

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to en
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
8. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... tightening technologyOCEANSIDE, N.Y., May 18 Ellman International, ... Administration (FDA) has granted clearance to Pelleve(TM), a ... mild to moderate facial wrinkles and rhytids for ... on clinical data demonstrating that a single treatment ...
... 18 When treating the diabetes ... all" approach to testing is not enough to ... at the American Association of Clinical Endocrinologists (AACE) ... http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ) "We need to ...
Cached Medicine Technology:Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 2Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 3Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient 2
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... "I had a handicapped friend who could ... an inventor from Wetumpka, Ala. "In order to help her ... shore, I came up with a way for her to ... prototype for the patent-pending Deezers to allow crutches to be ... use crutches, walkers, or canes at the beach. The device ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... 2014 The new review published by Daily ... by Karen Brimeyer, who wanted to make her guide accessible ... guide is now easy to find in the form of ... guide, the author of the new method shares all her ... Gossip writes in its review that the leaky gut syndrome ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... ... Chief Executive ... Barr Laboratories, Inc., -- In this newly created ... and development, regulatory affairs, operations, quality, and sales and ...
... DENVER, March 28 Long-chain (seafood) omega-3,polyunsaturated fatty ... heart,brain and eye health, according to recent research ... PUFA Newsletter electronic publications.,Groundbreaking studies also show that ... dry eye syndrome., The effect of fish ...
... delivery more likely if either parent was born that way, ... one or both parents were born bottom first or feet ... twice as likely to be born the same way, Norwegian ... about one in 20 is born bottom first. Breech deliveries ...
... people and their families living with ... all types of ... hit television series "Heroes" and father of an 11-year-old son with,epilepsy ... to plan community awareness activities that will empower other,people living with ...
... 27 SEIU Spokesperson,Andrew McDonald said:, ... UHW-W leaders should focus on,helping 70,000 ... year. UHW-W members,deserve better than to ... by a distracted,UHW-W leadership.", For ...
... On March 25, 2008, The Honorable Dan,A. Polster, ... Liability Multi-District Litigation in the Northern District,of Ohio, ... Steering,Committee. One of these lawyers is Peter Burg ... Polster, and is responsible for conducting,pre-trial proceedings on ...
Cached Medicine News:Health News:Barr Pharmaceuticals, Inc. Executive Bios 2Health News:Barr Pharmaceuticals, Inc. Executive Bios 3Health News:Barr Pharmaceuticals, Inc. Executive Bios 4Health News:Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes 2Health News:Breech Birth May Be Determined by Genes 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: